AstraZeneca

AstraZeneca's Bydureon fails to show cardio-protection
AstraZeneca's Bydureon fails to show cardio-protection
BioPharma Dive
EASD
AstraZeneca
Bydureon
diabetes
Flag link:
AstraZeneca's latest sale rakes in $555M
AstraZeneca's latest sale rakes in $555M
BioPharma Dive
AstraZeneca
M&A
Diprivan
Naropin
Carbocaine
Aspen Global
Flag link:
EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study
EASD: AstraZeneca's Farxiga cuts blood sugar, weight and insulin use in Type 1 study
Fierce Pharma
EASD
AstraZeneca
Farixga
diabetes
Flag link:
AstraZeneca and Moderna take a big, early step forward in their quest to prove mRNA works in humans
AstraZeneca and Moderna take a big, early step forward in their quest to prove mRNA works in humans
Endpoints
AstraZeneca
Moderna
MRNA
AZD-8601
Flag link:
AstraZeneca's Asthma Candidate Shows Promising Results
AstraZeneca's Asthma Candidate Shows Promising Results
Yahoo/Zacks.com
AstraZeneca
asthma
benralizumab
Flag link:
AstraZeneca CEO, worried by Brexit, not signing UK government letter
AstraZeneca CEO, worried by Brexit, not signing UK government letter
Yahoo/Reuters
AstraZeneca
UK
Brexit
Pharma CEOs
Pascal Soriot
Flag link:
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
ESMO: AstraZeneca wows with Imfinzi's 11-month survival edge in lung cancer
Fierce Pharma
ESMO
AstraZeneca
Imfinzi
lung cancer
Flag link:
AstraZeneca targeting California-based Acadia Pharmaceuticals ($4.4bn)
AstraZeneca targeting California-based Acadia Pharmaceuticals ($4.4bn)
GoInPharma
AstraZeneca
M&A
Acadia
Flag link:
ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth
ESMO: AstraZeneca's Tagrisso bests rivals at holding off EGFR lung cancer growth
Fierce Pharma
AstraZeneca
ESMO
Tagrisso
Flag link:
AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug
AstraZeneca, Amgen whip up some blockbuster excitement with a possible game-changing asthma drug
Endpoints
AstraZeneca
Amgen
tezepelumab
asthma
Flag link:
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
Yahoo/Zacks.com
Parkinson's Disease
Novartis
Teva Pharmaceutial
UCB Pharma
MEDI1341
AstraZeneca
Takeda
PRX002
Prothena
Roche
Acorda
Inbrija
Adamas Pharmaceuticals
Gocovri
Flag link:
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Daiichi Sankyo douses a report about an AstraZeneca buyout offer
Endpoints
AstraZeneca
Daiichi Sankyo
M&A
Flag link:
AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson’s deal
AstraZeneca auctions off rights to another pipeline drug as Takeda grabs $400M Parkinson’s deal
Endpoints
AstraZeneca
Takeda
MEDI1341
Parkinson's Disease
Flag link:
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
AstraZeneca's Faslodex Gets FDA Nod in First-Line Setting
Yahoo/Zacks.com
AstraZeneca
Faslodex
FDA
advanced breast cancer
Flag link:
With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC
With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC
Fierce Pharma
AstraZeneca
Brilinta
blood thinners
Flag link:
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
Pfizer's Ibrance in First-Line Combo Breast Cancer Study
Yahoo/Zacks.com
Pfizer
Ibrance
breast cancer
Faslodex
AstraZeneca
Flag link:
Struggling AstraZeneca ups the ante on mRNA pipeline work
Struggling AstraZeneca ups the ante on mRNA pipeline work
Endpoints
AstraZeneca
MRNA
R&D
Ethris
respiratory health
Flag link:
Ovarian Cancer Market Still Up For Grabs
Ovarian Cancer Market Still Up For Grabs
Barron's
ovarian cancer
Lynparza
Tesaro
AstraZeneca
Clovis Oncology
Flag link:
Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza
Watch out Tesaro, AstraZeneca and Merck get FDA OK for broad use of Lynparza
Endpoints
Tesaro
AstraZeneca
Merck
FDA
Lynparza
Zejula
Flag link:
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
The decade's top 10 patent losses, worth a whopping $915B in lifetime sales
Fierce Pharma
patents
AbbVie
Humira
Pfizer
Lipitor
Norvasc
GSK
Advair
Sanofi
Lantus
JNJ
Remicade
AstraZeneca
Crestor
Nexium
Amgen
Neulasta
Novartis
Diovan
Flag link: